{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:12:52Z","timestamp":1786720372246,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Haemophilia bears substantial humanistic and economic burden on children and their caregivers. Characterising the differential impact of severe versus moderate paediatric haemophilia is important for clinical and health policy decisions. We analysed health-related quality of life (HRQoL), annual direct medical (excluding factor treatment costs), non-medical and societal costs among children and adolescents with moderate and severe haemophilia A or B without inhibitors from the European CHESS-PAEDs study. Information was reported by physicians and caregivers; patients aged \u2265\u20098\u00a0years self-reported their HRQoL. Descriptive statistics summarised demographic and clinical characteristics, costs, and HRQoL scores (EQ-5D-Y). Regression models estimated differences in HRQoL and costs for moderate versus severe haemophilia adjusting for age, body mass index z-score, country, number of comorbidities, and weight-adjusted annual clotting factor consumption.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analytic sample comprised 794 patients with a mean age of 10.5\u00a0years; most had haemophilia A (79%) and 58% had severe haemophilia. Mean predicted direct medical costs in moderate patients were two-thirds of the predicted costs for severe disease (\u20ac3065 vs. \u20ac2047; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; N\u2009=\u2009794), while societal costs were more than half of the predicted costs for children with severe haemophilia (\u20ac6950 vs. \u20ac3666; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; N\u2009=\u2009220). Mean predicted HRQoL scores were 0.74 and 0.69 for moderate and severe disease, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05; N\u2009=\u2009185).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Children with haemophilia and their caregivers displayed a significant economic and humanistic burden. While severe patients showed the highest direct medical and societal costs, and worse HRQoL, the burden of moderate haemophilia on its own was substantial and far from negligible.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02301-0","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:04:08Z","timestamp":1649073848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-3239","authenticated-orcid":false,"given":"Idaira","family":"Rodriguez-Santana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pronabesh","family":"DasMahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Bartelt-Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"2301_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171:540\u20136.","journal-title":"Ann Intern Med"},{"key":"2301_CR2","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935\u20139.","journal-title":"J Thromb Haemost"},{"key":"2301_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/hae.13214","volume":"23","author":"M Witkop","year":"2017","unstructured":"Witkop M, Neff A, Buckner TW, Wang M, Batt K, Kessler CM, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017;23:556\u201365.","journal-title":"Haemophilia"},{"key":"2301_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/PPA.S212723","volume":"13","author":"ML Witkop","year":"2019","unstructured":"Witkop ML, Lambing A, Nichols CD, Munn JE, Anderson TL, Tortella BJ. Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey. Patient Prefer Adherence. 2019;13:1577\u201387.","journal-title":"Patient Prefer Adherence"},{"key":"2301_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/hae.13684","volume":"25","author":"S von Mackensen","year":"2019","unstructured":"von Mackensen S, Myrin Westesson L, Kavakli K, Klukowska A, Escuriola C, Uitslager N, et al. The impact of psychosocial determinants on caregivers\u2019 burden of children with haemophilia (results of the BBC study). Haemophilia. 2019;25:424\u201332.","journal-title":"Haemophilia"},{"key":"2301_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16704","volume":"190","author":"R Rayment","year":"2020","unstructured":"Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S, et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020;190:684\u201395.","journal-title":"Br J Haematol"},{"key":"2301_CR7","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1111\/jocn.15003","volume":"28","author":"L Myrin Westesson","year":"2019","unstructured":"Myrin Westesson L, Sparud-Lundin C, Baghaei F, Khair K, von Mackensen S, Acu\u00f1a Mora M, et al. Burden on parents of children with haemophilia: the impact of sociodemographic and child\u2019s medical condition. J Clin Nurs. 2019;28:4077\u201386.","journal-title":"J Clin Nurs"},{"issue":"Suppl 1","key":"2301_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, Kodra Y, Armeni P, De Santis M, L\u00f3pez-Bastida J, Linertov\u00e1 R, et al. Social\/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53\u201365.","journal-title":"Eur J Health Econ"},{"key":"2301_CR9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jval.2017.04.017","volume":"20","author":"CX Chen","year":"2017","unstructured":"Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Health. 2017;20:1074\u201382.","journal-title":"Value Health"},{"key":"2301_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/21556660.2019.1658306","volume":"8","author":"N Li","year":"2019","unstructured":"Li N, Sawyer EK, Maruszczyk K, Slomka M, Burke T, Martin AP, et al. Economic burden of hemophilia B in the US: a systematic literature review. J Drug Assess. 2019;8:28.","journal-title":"J Drug Assess"},{"key":"2301_CR11","first-page":"643","volume":"24","author":"BJ Tortella","year":"2018","unstructured":"Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, et al. Real-world analysis of dispensed IUs of coagulation factor IX and resultant expenditures in hemophilia B patients receiving standard half-life versus extended half-life products and those switching from standard half-life to extended half-life products. J Manag Care Spec Pharm. 2018;24:643\u201353.","journal-title":"J Manag Care Spec Pharm"},{"key":"2301_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/01621459.1979.10481634","volume":"74","author":"RD Cook","year":"1979","unstructured":"Cook RD. Influential observations in linear regression. J Am Stat Assoc. 1979;74:169\u201374.","journal-title":"J Am Stat Assoc"},{"key":"2301_CR13","unstructured":"Kelly E, Lee T, Sibieta L, Waters T. Public spending on children in England: 2000 to 2020: Institute for Fiscal Studies; 2018."},{"key":"2301_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20:205\u201316.","journal-title":"Eur J Health Econ"},{"key":"2301_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1160\/TH15-08-0637","volume":"115","author":"A Nijdam","year":"2016","unstructured":"Nijdam A, Foppen W, De Kleijn P, Mauser-Bunschoten EP, Roosendaal G, van Galen KP, et al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost. 2016;115:931\u20138.","journal-title":"Thromb Haemost"},{"key":"2301_CR16","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1111\/hae.13546","volume":"24","author":"J O'Hara","year":"2018","unstructured":"O\u2019Hara J, Sima CS, Frimpter J, Paliargues F, Chu P, Presch I. Long-term outcomes from prophylactic or episodic treatment of haemophilia A: a systematic review. Haemophilia. 2018;24:e301\u201311.","journal-title":"Haemophilia"},{"key":"2301_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1160\/TH14-05-0407","volume":"114","author":"A Tagliaferri","year":"2015","unstructured":"Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 2015;114:35\u201345.","journal-title":"Thromb Haemost"},{"key":"2301_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys. Orphanet J Rare Dis. 2021;16:143.","journal-title":"Orphanet J Rare Dis"},{"key":"2301_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","volume":"12","author":"J O'Hara","year":"2017","unstructured":"O\u2019Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12:106.","journal-title":"Orphanet J Rare Dis"},{"key":"2301_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337\u201343.","journal-title":"Ann Med"},{"key":"2301_CR21","unstructured":"Percentile Data Files with LMS Values. Centers for Disease Control and Prevention, 2000. at https:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm."},{"key":"2301_CR22","unstructured":"O\u2019Hara J, Khair K, McLaughlin P, et al. \u201cProblem Joint\u201d a more patient relevant definition for joint morbidity in haemophilia. Haemophilia 2019;25(S1):111\u20132 (abstract 154)."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02301-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:10:40Z","timestamp":1649074240000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02301-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Sub Committee of the Faculty of Health and Social care within the University of Chester and was conducted in correspondence with regional and relevant guidelines. It was conducted in collaboration with the UK Haemophilia Society and governed by a steering committee chaired by Dr Kate Khair. Patient consent was obtained via tick box selection for the patient-reported element of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}